Base de dados : MEDLINE
Pesquisa : D12.644.541.500.697.249 [Categoria DeCS]
Referências encontradas : 71 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 8 ir para página                    

  1 / 71 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26416571
[Au] Autor:Webb NE; Montefiori DC; Lee B
[Ad] Endereço:Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, California 90024, USA.
[Ti] Título:Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies.
[So] Source:Nat Commun;6:8443, 2015 Sep 29.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A new generation of HIV broadly neutralizing antibodies (bnAbs) with remarkable potency, breadth and epitope diversity has rejuvenated interest in immunotherapeutic strategies. Potencies defined by in vitro IC50 and IC80 values (50 and 80% inhibitory concentrations) figure prominently into the selection of clinical candidates; however, much higher therapeutic levels will be required to reduce multiple logs of virus and impede escape. Here we predict bnAb potency at therapeutic levels by analysing dose-response curve slopes, and show that slope is independent of IC50/IC80 and specifically relates to bnAb epitope class. With few exceptions, CD4-binding site and V3-glycan bnAbs exhibit slopes >1, indicative of higher expected therapeutic effectiveness, whereas V2-glycan, gp41 membrane-proximal external region (MPER) and gp120-gp41 bnAbs exhibit less favourable slopes <1. Our results indicate that slope is one major predictor of both potency and breadth for bnAbs at clinically relevant concentrations, and may better coordinate the relationship between bnAb epitope structure and therapeutic expectations.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/uso terapêutico
HIV/imunologia
[Mh] Termos MeSH secundário: Especificidade de Anticorpos
Imunoadesinas CD4/uso terapêutico
Relação Dose-Resposta a Droga
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (CD4 Immunoadhesins)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150930
[St] Status:MEDLINE
[do] DOI:10.1038/ncomms9443


  2 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23427154
[Au] Autor:Gavrilyuk J; Ban H; Uehara H; Sirk SJ; Saye-Francisco K; Cuevas A; Zablowsky E; Oza A; Seaman MS; Burton DR; Barbas CF
[Ad] Endereço:Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA.
[Ti] Título:Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.
[So] Source:J Virol;87(9):4985-93, 2013 May.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Broadly neutralizing antibodies PG9 and PG16 effectively neutralize 70 to 80% of circulating HIV-1 isolates. In this study, the neutralization abilities of PG9 and PG16 were further enhanced by bioconjugation with aplaviroc, a small-molecule inhibitor of virus entry into host cells. A novel air-stable diazonium hexafluorophosphate reagent that allows for rapid, tyrosine-selective functionalization of proteins and antibodies under mild conditions was used to prepare a series of aplaviroc-conjugated antibodies, including b12, 2G12, PG9, PG16, and CD4-IgG. The conjugated antibodies blocked HIV-1 entry through two mechanisms: by binding to the virus itself and by blocking the CCR5 receptor on host cells. Chemical modification did not significantly alter the potency of the parent antibodies against nonresistant HIV-1 strains. Conjugation did not alter the pharmacokinetics of a model IgG in blood. The PG9-aplaviroc conjugate was tested against a panel of 117 HIV-1 strains and was found to neutralize 100% of the viruses. PG9-aplaviroc conjugate IC50s were lower than those of PG9 in neutralization studies of 36 of the 117 HIV-1 strains. These results support this new approach to bispecific antibodies and offer a potential new strategy for combining HIV-1 therapies.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/imunologia
Imunoadesinas CD4/imunologia
Anticorpos Anti-HIV/imunologia
Infecções por HIV/imunologia
HIV-1/imunologia
Imunoconjugados/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/química
Anticorpos Neutralizantes/farmacologia
Benzoatos/química
Benzoatos/farmacologia
Imunoadesinas CD4/química
Imunoadesinas CD4/farmacologia
Linhagem Celular
Anticorpos Anti-HIV/química
Anticorpos Anti-HIV/farmacologia
Infecções por HIV/tratamento farmacológico
Infecções por HIV/virologia
HIV-1/efeitos dos fármacos
HIV-1/fisiologia
Seres Humanos
Imunoconjugados/química
Imunoconjugados/farmacologia
Testes de Neutralização
Piperazinas/química
Piperazinas/farmacologia
Compostos de Espiro/química
Compostos de Espiro/farmacologia
Internalização do Vírus/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Benzoates); 0 (CD4 Immunoadhesins); 0 (HIV Antibodies); 0 (Immunoconjugates); 0 (Piperazines); 0 (Spiro Compounds); 98B425P30V (aplaviroc)
[Em] Mês de entrada:1307
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130222
[St] Status:MEDLINE
[do] DOI:10.1128/JVI.03146-12


  3 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23238748
[Au] Autor:Balazs AB; West AP
[Ad] Endereço:Division of Biology, California Institute of Technology, Pasadena, California, USA.
[Ti] Título:Antibody gene transfer for HIV immunoprophylaxis.
[So] Source:Nat Immunol;14(1):1-5, 2013 Jan.
[Is] ISSN:1529-2916
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antibody gene transfer, which involves the delivery of genes that encode potent, broadly neutralizing antibodies to human immunodeficiency virus (HIV), is a promising new strategy for preventing HIV infection. A satellite symposium at the AIDS Vaccine 2012 conference brought together many of the groups working in this field.
[Mh] Termos MeSH primário: Vacinas contra a AIDS/genética
Anticorpos Neutralizantes/genética
Anticorpos Antivirais/genética
Técnicas de Transferência de Genes
Infecções por HIV/prevenção & controle
HIV/imunologia
[Mh] Termos MeSH secundário: Animais
Imunoadesinas CD4/genética
Imunoadesinas CD4/imunologia
Ensaios Clínicos como Assunto
Dependovirus
Modelos Animais de Doenças
Engenharia Genética
Vetores Genéticos/genética
Seres Humanos
Células Musculares/imunologia
Estados Unidos
[Pt] Tipo de publicação:CONGRESSES; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (AIDS Vaccines); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (CD4 Immunoadhesins)
[Em] Mês de entrada:1303
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121215
[St] Status:MEDLINE
[do] DOI:10.1038/ni.2480


  4 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22079291
[Au] Autor:Rathore YS; Solanki AK; Dhoke RR; Ashish
[Ad] Endereço:Institute of Microbial Technology (CSIR), Chandigarh, India.
[Ti] Título:SAXS data analysis and modeling of tetravalent neutralizing antibody CD4-IgG2 -/+ HIV-1 gp120 revealed that first two gp120 bind to the same Fab arm.
[So] Source:Biochem Biophys Res Commun;415(4):680-5, 2011 Dec 02.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This communication describes SAXS data based global structures of tetravalent antibody CD4-IgG2 and its dimeric to pentameric complexes with gp120s. Comparison of models brought forth that while the two CD4s grafted on each arm remain tightly packed in the unliganded antibody, they enable binding of first two gp120s preferentially to the same Fab arm in an asymmetric manner. Retention of residues in the CD4-Fab linker earlier reasoned to enable bi-fold collapse of gp120-bound soluble CD4, and observed asymmetry of the (CD4-IgG2)/(gp120)(2) complex suggest that encoded flexibility in CD4-Fab linker is a critical structure-function factor for this broad spectrum neutralizing antibody.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/química
Imunoadesinas CD4/química
Proteína gp120 do Envelope de HIV/imunologia
HIV-1/imunologia
Fragmentos Fab das Imunoglobulinas/química
Modelos Químicos
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/imunologia
Imunoadesinas CD4/imunologia
Seres Humanos
Fragmentos Fab das Imunoglobulinas/imunologia
Espalhamento a Baixo Ângulo
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (CD4 Immunoadhesins); 0 (CD4-IgG(2)); 0 (HIV Envelope Protein gp120); 0 (Immunoglobulin Fab Fragments)
[Em] Mês de entrada:1201
[Cu] Atualização por classe:111205
[Lr] Data última revisão:
111205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111115
[St] Status:MEDLINE
[do] DOI:10.1016/j.bbrc.2011.10.136


  5 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:19448633
[Au] Autor:Johnson PR; Schnepp BC; Zhang J; Connell MJ; Greene SM; Yuste E; Desrosiers RC; Clark KR
[Ad] Endereço:The Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. johnsonphi@chop.edu
[Ti] Título:Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.
[So] Source:Nat Med;15(8):901-6, 2009 Aug.
[Is] ISSN:1546-170X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The key to an effective HIV vaccine is development of an immunogen that elicits persisting antibodies with broad neutralizing activity against field strains of the virus. Unfortunately, very little progress has been made in finding or designing such immunogens. Using the simian immunodeficiency virus (SIV) model, we have taken a markedly different approach: delivery to muscle of an adeno-associated virus gene transfer vector expressing antibodies or antibody-like immunoadhesins having predetermined SIV specificity. With this approach, SIV-specific molecules are endogenously synthesized in myofibers and passively distributed to the circulatory system. Using such an approach in monkeys, we have now generated long-lasting neutralizing activity in serum and have observed complete protection against intravenous challenge with virulent SIV. In essence, this strategy bypasses the adaptive immune system and holds considerable promise as a unique approach to an effective HIV vaccine.
[Mh] Termos MeSH primário: Anticorpos Antivirais/imunologia
Vetores Genéticos/imunologia
Haplorrinos/imunologia
Vacinas contra a SAIDS/uso terapêutico
Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle
Vírus da Imunodeficiência Símia/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/metabolismo
Imunoadesinas CD4/imunologia
Técnicas de Transferência de Genes/veterinária
Haplorrinos/genética
Imunoterapia/métodos
Imunoterapia/veterinária
Modelos Biológicos
Testes de Neutralização
Vacinas contra a SAIDS/genética
Síndrome de Imunodeficiência Adquirida dos Símios/sangue
Síndrome de Imunodeficiência Adquirida dos Símios/imunologia
Resultado do Tratamento
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (CD4 Immunoadhesins); 0 (SAIDS Vaccines)
[Em] Mês de entrada:0908
[Cu] Atualização por classe:161122
[Lr] Data última revisão:
161122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090519
[St] Status:MEDLINE
[do] DOI:10.1038/nm.1967


  6 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17667814
[Au] Autor:Lutz J; Lu R; Strobl M; Huang H; Deng M; Wang M; Ouyang N; Heemann U
[Ad] Endereço:Department of Nephrology, Klinikum rechts der Isar, Munich, Germany.
[Ti] Título:ICOS/B7RP-1 interference in mouse kidney transplantation.
[So] Source:Transplantation;84(2):223-30, 2007 Jul 27.
[Is] ISSN:0041-1337
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Activated T cells play a key role in allograft rejection. T cell activation requires signaling via the T cell receptor as well as costimulatory signals. Inducible costimulatory molecule (ICOS), with its ligand B7RP-1, is a recently discovered costimulatory molecule of the CD28 family. The role of this signaling pathway during the early phases of kidney allograft rejection is not clear so far. METHODS: Kidneys were orthotopically transplanted from BALB/c to C57BL/6 mice. Animals were assigned to five experimental groups: blocking anti-ICOS monoclonal antibody, ICOS fusion protein, anti-B7RP1 monoclonal antibody, B7RP-1 fusion protein, and control immunoglobulin G. RESULTS: Survival was significantly reduced in animals treated with ICOS monoclonal antibody (mAb) and B7RP-1 Fc as compared with controls. These animals had also a lower number of apoptotic graft infiltrating T cells, whereas the expression of intracellular interferon-gamma in CD3CD4 T cells was increased. Animals treated with ICOS Fc and B7RP-1 mAb had similar survival and numbers of apoptotic T cells as compared with controls. CONCLUSIONS: In summary, the blockade of ICOS with ICOS mAb or B7RP-1 Fc reduced the amount of apoptosis of infiltrating lymphocytes and resulted in continuous inflammatory processes with progressive tissue damage and graft failure.
[Mh] Termos MeSH primário: Antígenos de Diferenciação de Linfócitos T/uso terapêutico
Antígeno B7-1/uso terapêutico
Rejeição de Enxerto/tratamento farmacológico
Transplante de Rim/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Monoclonais
Antígenos de Diferenciação de Linfócitos T/imunologia
Apoptose
Antígeno B7-1/imunologia
Complexo CD3/biossíntese
Complexo CD3/genética
Imunoadesinas CD4/biossíntese
Imunoadesinas CD4/genética
Modelos Animais de Doenças
Citometria de Fluxo
Expressão Gênica
Rejeição de Enxerto/imunologia
Rejeição de Enxerto/metabolismo
Sobrevivência de Enxerto
Marcação In Situ das Extremidades Cortadas
Ligante Coestimulador de Linfócitos T Induzíveis
Proteína Coestimuladora de Linfócitos T Induzíveis
Líquido Intracelular/metabolismo
Transplante de Rim/patologia
Ligantes
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos C57BL
RNA Mensageiro/genética
Linfócitos T/imunologia
Linfócitos T/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antigens, Differentiation, T-Lymphocyte); 0 (B7-1 Antigen); 0 (CD3 Complex); 0 (CD3 antigen, gamma chain); 0 (CD4 Immunoadhesins); 0 (Icos protein, mouse); 0 (Inducible T-Cell Co-Stimulator Ligand); 0 (Inducible T-Cell Co-Stimulator Protein); 0 (Ligands); 0 (RNA, Messenger)
[Em] Mês de entrada:0708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:070802
[St] Status:MEDLINE


  7 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:17336619
[Au] Autor:Fletcher CV; DeVille JG; Samson PM; Moye JH; Church JA; Spiegel HM; Palumbo P; Fenton T; Smith ME; Graham B; Kraimer JM; Shearer WT; Pediatric AIDS Clinical Trials Group, Protocol 351 Study Group
[Ti] Título:Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.
[So] Source:J Allergy Clin Immunol;119(3):747-50, 2007 Mar.
[Is] ISSN:0091-6749
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Imunoadesinas CD4/administração & dosagem
Infecções por HIV/tratamento farmacológico
HIV-1
Proteínas Recombinantes de Fusão/administração & dosagem
Proteínas Recombinantes de Fusão/farmacocinética
[Mh] Termos MeSH secundário: Criança
Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:CLINICAL TRIAL; LETTER; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (CD4 Immunoadhesins); 0 (CD4-IgG(2)); 0 (Recombinant Fusion Proteins)
[Em] Mês de entrada:0704
[Cu] Atualização por classe:161122
[Lr] Data última revisão:
161122
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:070306
[St] Status:MEDLINE


  8 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:17092531
[Au] Autor:Dey AK; David KB; Klasse PJ; Moore JP
[Ad] Endereço:Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W-805, New York, NY 10021, USA.
[Ti] Título:Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
[So] Source:Virology;360(1):199-208, 2007 Mar 30.
[Is] ISSN:0042-6822
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The HIV-1 envelope glycoprotein is expressed on the viral membrane as a trimeric complex, formed by three gp120 surface glycoproteins non-covalently associated with three membrane-anchored gp41 subunits. The labile nature of the association between gp120 and gp41 hinders the expression of soluble, fully cleaved, trimeric gp140 proteins for structural and immunization studies. Disruption of the primary cleavage site within gp160 allows the production of stable gp140 trimers, but cleavage-defective trimers are antigenically dissimilar from their cleaved counterparts. Soluble, stabilized, proteolytically cleaved, trimeric gp140 proteins can be generated by engineering an intermolecular disulfide bond between gp120 and gp41 (SOS), combined with a single residue change, I559P, within gp41 (SOSIP). We have found that SOSIP gp140 proteins based on the subtype A HIV-1 strain KNH1144 form particularly homogenous trimers compared to a prototypic strain (JR-FL, subtype B). We now show that the determinants of this enhanced stability are located in the N-terminal region of KNH11144 gp41 and that, when substituted into heterologous Env sequences (e.g., JR-FL and Ba-L) they have a similarly beneficial effect on trimer stability. The stabilized trimers retain the epitopes for several neutralizing antibodies (b12, 2G12, 2F5 and 4E10) and the CD4-IgG2 molecule, suggesting that the overall antigenic structure of the gp140 protein has not been adversely impaired by the trimer-stabilizing substitutions. The ability to increase the stability of gp140 trimers might be useful for neutralizing antibody-based vaccine strategies based on the use of this type of immunogen.
[Mh] Termos MeSH primário: Produtos do Gene env/metabolismo
Proteína gp41 do Envelope de HIV/química
HIV-1/química
Estrutura Terciária de Proteína/fisiologia
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Anticorpos Monoclonais
Imunoadesinas CD4/imunologia
Linhagem Celular
Epitopos/imunologia
Produtos do Gene env/imunologia
Anticorpos Anti-HIV/imunologia
HIV-1/imunologia
Seres Humanos
Dados de Sequência Molecular
Testes de Neutralização
Alinhamento de Sequência
Solubilidade
Relação Estrutura-Atividade
Produtos do Gene env do Vírus da Imunodeficiência Humana
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (CD4 Immunoadhesins); 0 (Epitopes); 0 (Gene Products, env); 0 (HIV Antibodies); 0 (HIV Envelope Protein gp41); 0 (env Gene Products, Human Immunodeficiency Virus); 0 (gp140 envelope protein, Human immunodeficiency virus 1)
[Em] Mês de entrada:0705
[Cu] Atualização por classe:161203
[Lr] Data última revisão:
161203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:061110
[St] Status:MEDLINE


  9 / 71 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17157668
[Au] Autor:Williamson MP; McCormick TG; Nance CL; Shearer WT
[Ad] Endereço:Department of Molecular Biology and Biotechnology, University of Sheffield, United Kingdom.
[Ti] Título:Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
[So] Source:J Allergy Clin Immunol;118(6):1369-74, 2006 Dec.
[Is] ISSN:0091-6749
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The green tea flavonoid, epigallocatechin gallate (EGCG), has been proposed to have an anti-HIV-1 effect by preventing the binding of HIV-1 glycoprotein (gp) 120 to the CD4 molecule on T cells. OBJECTIVE: To demonstrate that EGCG binds to the CD4 molecule at the gp120 attachment site and inhibits gp120 binding at physiologically relevant levels, thus establishing EGCG as a potential therapeutic treatment for HIV-1 infection. METHODS: Nuclear magnetic resonance spectroscopy was used to examine the binding of EGCG and control, (-)-catechin, to CD4-IgG2 (PRO 542). Gp120 binding to human CD4+ T cells was analyzed by flow cytometry. RESULTS: Addition of CD4 to EGCG produced a linear decrease in nuclear magnetic resonance signal intensity from EGCG but not from the control, (-)-catechin. In saturation transfer difference experiments, addition of 5.8 micromol/L CD4 to 310 micromol/L EGCG produced strong saturation at the aromatic rings of EGCG, but identical concentrations of (-)-catechin produced much smaller effects, implying EGCG/CD4 binding strong enough to reduce gp120/CD4 binding substantially. Molecular modeling studies suggested a binding site for EGCG in the D1 domain of CD4, the pocket that binds gp120. Physiologically relevant concentrations of EGCG (0.2 micromol/L) inhibited binding of gp120 to isolated human CD4+ T cells. CONCLUSION: We have demonstrated clear evidence of high-affinity binding of EGCG to the CD4 molecule with a Kd of approximately 10 nmol/L and inhibition of gp120 binding to human CD4+ T cells. CLINICAL IMPLICATIONS: Epigallocatechin gallate has potential use as adjunctive therapy in HIV-1 infection.
[Mh] Termos MeSH primário: Antígenos CD4/metabolismo
Catequina/análogos & derivados
HIV-1
Inibidores de Proteases/metabolismo
[Mh] Termos MeSH secundário: Sítios de Ligação
Imunoadesinas CD4/metabolismo
Catequina/química
Catequina/metabolismo
Flavonoides
Proteína gp120 do Envelope de HIV/metabolismo
Infecções por HIV/tratamento farmacológico
Infecções por HIV/imunologia
Seres Humanos
Espectroscopia de Ressonância Magnética
Modelos Moleculares
Fenóis
Polifenóis
Receptores de HIV/metabolismo
Chá/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (CD4 Antigens); 0 (CD4 Immunoadhesins); 0 (CD4-IgG(2)); 0 (Flavonoids); 0 (HIV Envelope Protein gp120); 0 (Phenols); 0 (Polyphenols); 0 (Protease Inhibitors); 0 (Receptors, HIV); 0 (Tea); 8R1V1STN48 (Catechin); BQM438CTEL (epigallocatechin gallate)
[Em] Mês de entrada:0702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:061213
[St] Status:MEDLINE


  10 / 71 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:16890780
[Au] Autor:Shearer WT; DeVille JG; Samson PM; Moye JH; Fletcher CV; Church JA; Spiegel HM; Palumbo P; Fenton T; Smith ME; Graham B; Kraimer JM; Olson WC
[Ti] Título:Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
[So] Source:J Allergy Clin Immunol;118(2):518-21, 2006 Aug.
[Is] ISSN:0091-6749
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais/farmacologia
Imunoadesinas CD4/farmacologia
Anticorpos Anti-HIV/farmacologia
HIV-1/efeitos dos fármacos
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados
Criança
Pré-Escolar
HIV-1/isolamento & purificação
Seres Humanos
Técnicas In Vitro
Receptores CCR5/imunologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; LETTER; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (CD4 Immunoadhesins); 0 (CD4-IgG(2)); 0 (HIV Antibodies); 0 (PRO-140 monoclonal antibody); 0 (Receptors, CCR5)
[Em] Mês de entrada:0609
[Cu] Atualização por classe:141124
[Lr] Data última revisão:
141124
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:060808
[St] Status:MEDLINE



página 1 de 8 ir para página                    
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde